PharmaCyte Biotech (PMCB) Competitors $1.62 +0.01 (+0.31%) Closing price 01/31/2025 03:58 PM EasternExtended Trading$1.60 -0.02 (-1.23%) As of 01/31/2025 05:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsOptions ChainOwnershipSEC FilingsShort InterestTrends PMCB vs. ALRN, NBRV, KZR, VTVT, DYAI, TNXP, ATNM, ESLA, SCYX, and ITRMShould you be buying PharmaCyte Biotech stock or one of its competitors? The main competitors of PharmaCyte Biotech include Aileron Therapeutics (ALRN), Nabriva Therapeutics (NBRV), Kezar Life Sciences (KZR), vTv Therapeutics (VTVT), Dyadic International (DYAI), Tonix Pharmaceuticals (TNXP), Actinium Pharmaceuticals (ATNM), Estrella Immunopharma (ESLA), SCYNEXIS (SCYX), and Iterum Therapeutics (ITRM). These companies are all part of the "pharmaceutical products" industry. PharmaCyte Biotech vs. Aileron Therapeutics Nabriva Therapeutics Kezar Life Sciences vTv Therapeutics Dyadic International Tonix Pharmaceuticals Actinium Pharmaceuticals Estrella Immunopharma SCYNEXIS Iterum Therapeutics Aileron Therapeutics (NASDAQ:ALRN) and PharmaCyte Biotech (NASDAQ:PMCB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, community ranking, media sentiment and profitability. Do insiders and institutionals have more ownership in ALRN or PMCB? 90.9% of Aileron Therapeutics shares are held by institutional investors. Comparatively, 34.2% of PharmaCyte Biotech shares are held by institutional investors. 5.1% of Aileron Therapeutics shares are held by company insiders. Comparatively, 1.0% of PharmaCyte Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has higher earnings & valuation, ALRN or PMCB? Aileron Therapeutics is trading at a lower price-to-earnings ratio than PharmaCyte Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAileron TherapeuticsN/AN/A-$15.73M-$3.12N/APharmaCyte BiotechN/AN/A$330K$0.533.07 Does the media prefer ALRN or PMCB? In the previous week, Aileron Therapeutics and Aileron Therapeutics both had 2 articles in the media. PharmaCyte Biotech's average media sentiment score of 1.44 beat Aileron Therapeutics' score of -0.50 indicating that PharmaCyte Biotech is being referred to more favorably in the news media. Company Overall Sentiment Aileron Therapeutics Negative PharmaCyte Biotech Positive Which has more risk & volatility, ALRN or PMCB? Aileron Therapeutics has a beta of 2.24, indicating that its share price is 124% more volatile than the S&P 500. Comparatively, PharmaCyte Biotech has a beta of -0.22, indicating that its share price is 122% less volatile than the S&P 500. Do analysts recommend ALRN or PMCB? Aileron Therapeutics presently has a consensus target price of $19.00, indicating a potential upside of 0.00%. Given Aileron Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aileron Therapeutics is more favorable than PharmaCyte Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aileron Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50PharmaCyte Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community favor ALRN or PMCB? Aileron Therapeutics received 213 more outperform votes than PharmaCyte Biotech when rated by MarketBeat users. CompanyUnderperformOutperformAileron TherapeuticsOutperform Votes21366.98% Underperform Votes10533.02% PharmaCyte BiotechN/AN/A Is ALRN or PMCB more profitable? PharmaCyte Biotech's return on equity of 0.76% beat Aileron Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aileron TherapeuticsN/A -74.08% -27.93% PharmaCyte Biotech N/A 0.76%0.45% SummaryAileron Therapeutics beats PharmaCyte Biotech on 8 of the 13 factors compared between the two stocks. Get PharmaCyte Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for PMCB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PMCB vs. The Competition Export to ExcelMetricPharmaCyte BiotechBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.24M$3.05B$5.57B$9.11BDividend YieldN/A1.84%5.32%3.99%P/E Ratio3.0745.7689.4218.28Price / SalesN/A319.021,253.4080.65Price / CashN/A190.0245.9637.70Price / Book0.504.125.124.70Net Income$330,000.00-$40.99M$111.33M$224.47M7 Day Performance-0.31%-0.40%2.33%-0.20%1 Month Performance3.50%0.96%3.19%0.57%1 Year Performance-26.64%-1.66%24.63%20.29% PharmaCyte Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PMCBPharmaCyte Biotech2.2119 of 5 stars$1.63+0.3%N/A-25.8%$11.24MN/A3.074Short Interest ↓Positive NewsALRNAileron Therapeutics3.0649 of 5 starsN/A$19.00+∞N/A$45.72MN/A0.009Short Interest ↑NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M-0.0770Analyst ForecastNews CoverageKZRKezar Life Sciences4.4887 of 5 stars$6.19-2.4%$39.50+538.1%-34.5%$45.19M$7M-0.4760Short Interest ↓Positive NewsHigh Trading VolumeVTVTvTv Therapeutics1.7648 of 5 stars$14.05flat$35.00+149.1%+85.7%$44.82M$2.02M-3.109Short Interest ↑News CoverageDYAIDyadic International3.1031 of 5 stars$1.50+0.7%$6.00+300.0%+14.6%$44.38M$3.36M-6.527Short Interest ↓Positive NewsGap UpTNXPTonix Pharmaceuticals3.0722 of 5 stars$0.24+0.2%$53.50+22,617.6%-95.8%$44.01M$7.77M0.0050Short Interest ↑News CoverageGap UpATNMActinium Pharmaceuticals1.6179 of 5 stars$1.40+14.8%$7.40+428.6%-78.4%$43.68M$80,000.00-1.0130ESLAEstrella Immunopharma0.5022 of 5 stars$1.19+1.5%N/A-6.2%$43.05MN/A-4.58N/AShort Interest ↓Positive NewsSCYXSCYNEXIS0.9504 of 5 stars$1.12-1.8%N/A-48.1%$42.50M$8.57M-1.5160Positive NewsITRMIterum Therapeutics2.1473 of 5 stars$1.54flat$5.00+224.7%+3.9%$42.38MN/A-0.7710Short Interest ↓News CoveragePositive News Related Companies and Tools Related Companies ALRN Competitors NBRV Competitors KZR Competitors VTVT Competitors DYAI Competitors TNXP Competitors ATNM Competitors ESLA Competitors SCYX Competitors ITRM Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PMCB) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredElon’s ultimate power move?THE ELON SHOCK All of Elon Musk’s strange behavior may soon make sense… and impact the markets in a way no ...Altimetry | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump loves DeepSeekPresident Trump could be ecstatic. And it's all thanks to DeepSeek. The secretive Chinese startup just r...Weiss Ratings | SponsoredNew catalyst on Wall Street’s radar for this week (NOT Trump)Wall Street is already looking past Trump… To a new catalyst on the near horizon that could be even bigger ...Timothy Sykes | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PharmaCyte Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PharmaCyte Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
